Upgrade to SI Premium - Free Trial

Truist Securities Reiterates Buy Rating on Biogen (BIIB)

October 28, 2024 8:49 AM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $302.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "At ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles